• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

    4/24/26 9:28:23 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRIX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Nurix Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    67080M103

    (CUSIP Number)
    04/20/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    Redmile Group, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,696,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,696,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,696,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of common stock, par value $0.001 per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile"), including RedCo II Offshore SPV LLC ("RedCo II SPV"), is incorporated by reference herein. Percentage based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q for the quarterly period ended February 28, 2026 filed with the Securities and Exchange Commission on April 8, 2026 (the "Form 10-Q") plus (ii) 3,664,406 shares of Common Stock issuable upon exercise of certain of the Pre-Funded Warrants to purchase Common Stock (the "Warrants") held directly by certain investment vehicles, including RedCo II SPV, managed by Redmile (the "Redmile Funds"), which due to the Beneficial Ownership Limitation (as defined in Item 4) is the maximum number of shares that could be issued to the Redmile Funds upon exercise of the Warrants.


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    Jeremy C. Green
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,696,314.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,696,314.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,696,314.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy C. Green is incorporated by reference herein. Percentage based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 3,664,406 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by the Redmile Funds, including RedCo II SPV, which due to the Beneficial Ownership Limitation (as defined in Item 4) is the maximum number of shares that could be issued to the Redmile Funds upon exercise of the Warrants.


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    RedCo II Offshore SPV LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,967,424.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,967,424.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,967,424.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    FI, OO

    Comment for Type of Reporting Person:  The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by RedCo II SPV is incorporated by reference herein. Percentage based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 2,881,142 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by RedCo II SPV.


    SCHEDULE 13G

    CUSIP Number(s):
    67080M103


    1Names of Reporting Persons

    RedCo II Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN, FI

    Comment for Type of Reporting Person:  Following the internal reorganization among certain Redmile Funds described in Item 4 below, RedCo II Master Fund, L.P. beneficially owned no shares of the Issuer's Common Stock.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nurix Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1600 Sierra Point Parkway Brisbane, CA 94005
    Item 2. 
    (a)Name of person filing:

    Redmile Group, LLC Jeremy C. Green RedCo II Offshore SPV LLC RedCo II Master Fund, L.P.
    (b)Address or principal business office or, if none, residence:

    Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 RedCo II Offshore SPV LLC c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939 RedCo II Master Fund, L.P. c/o Redmile Group, LLC 900 Larkspur Landing Circle, Suite 270 Larkspur, California 94939
    (c)Citizenship:

    Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom RedCo II Offshore SPV LLC: Cayman Islands RedCo II Master Fund, L.P.: Cayman Islands
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    67080M103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Redmile Group, LLC - 10,696,314 (1) Jeremy C. Green - 10,696,314 (1) RedCo II Offshore SPV LLC - 5,967,424 (2) RedCo II Master Fund, L.P. - 0
    (b)Percent of class:

    Redmile Group, LLC - 9.9% (3) Jeremy C. Green - 9.9% (3) RedCo II Offshore SPV LLC - 5.6% (4) RedCo II Master Fund, L.P. - 0.0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Offshore SPV LLC - 0 RedCo II Master Fund, L.P. - 0

     (ii) Shared power to vote or to direct the vote:

    Redmile Group, LLC - 10,696,314 (1) Jeremy C. Green - 10,696,314 (1) RedCo II Offshore SPV LLC - 5,967,424 (2) RedCo II Master Fund, L.P. - 0

     (iii) Sole power to dispose or to direct the disposition of:

    Redmile Group, LLC - 0 Jeremy C. Green - 0 RedCo II Offshore SPV LLC - 0 RedCo II Master Fund, L.P. - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Redmile Group, LLC - 10,696,314 (1) Jeremy C. Green - 10,696,314 (1) RedCo II Offshore SPV LLC - 5,967,424 (2) RedCo II Master Fund, L.P. - 0 (1) As of April 20, 2026, Redmile Group, LLC's and Jeremy Green's beneficial ownership of Common Stock is comprised of 7,031,908 shares of Common Stock owned by certain investment vehicles, including RedCo II Offshore SPV LLC ("RedCo II SPV"), for which Redmile Group, LLC ("Redmile") is the investment manager/adviser (the "Redmile Funds"). Subject to the Beneficial Ownership Blocker (as defined below), Redmile and Mr. Green may also be deemed to beneficially own 4,708,469 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants to purchase Common Stock (the "Warrants") held by the Redmile Funds, including RedCo II SPV. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of the Warrants, and a holder of any Warrants shall not be entitled to exercise the Warrants held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder's affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder's for the purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and the applicable regulations of the Securities and Exchange Commission, including any "group" of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (the "Beneficial Ownership Blocker"). The "Beneficial Ownership Limitation" is 9.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder's election upon 61 days' notice to the Issuer. The 10,696,314 shares of Common Stock reported as beneficially owned by Redmile in this Schedule 13G represent 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (3) below) and includes 3,664,406 shares of Common Stock issuable under the Beneficial Ownership Blocker. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such shares, if any. (2) On April 20, 2026, in connection with an internal reorganization of RedCo II Master Fund, L.P. ("RedCo II Master"), a private investment vehicle managed by Redmile, Redco II Master contributed all of its securities of the Issuer pro rata and in kind, for no consideration, to its two wholly-owned subsidiaries (collectively, the "SPVs"), including RedCo II SPV. As a result of the internal reorganization, (i) RedCo II Master ceased to have voting or dispositive power over any of the Issuer's securities and, therefore, is no longer a beneficial owner of more than 5% of the Issuer's Common Stock and will be dissolved, and (ii) RedCo II SPV became a beneficial owner of more than 5% of the Common Stock. The 5,967,424 shares of Common Stock reported as beneficially owned by RedCo II SPV includes 3,086,282 shares of Common Stock and 2,881,142 shares of Common Stock issuable upon exercise of the Warrants under the Beneficial Ownership Blocker. Accordingly, this Schedule 13G serves as an exit filing for RedCo II Master and as an initial filing for RedCo II SPV. The internal reorganization resulted in no change in the aggregate beneficial ownership of Redmile or Mr. Green. (3) Percentage for Redmile and Jeremy Green based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 3,664,406 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by the Redmile Funds, including RedCo II SPV, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued to the Redmile Funds upon exercise of the Warrants. (4) Percentage for RedCo II SPV based on (i) 103,405,813 shares of Common Stock outstanding as of April 1, 2026, as reported by the Issuer in its Form 10-Q plus (ii) 2,881,142 shares of Common Stock issuable upon exercise of certain of the Warrants held directly by RedCo II SPV.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See the response to Item 4.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Redmile Group, LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member
    Date:04/24/2026
     
    Jeremy C. Green
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Jeremy C. Green
    Date:04/24/2026
     
    RedCo II Offshore SPV LLC
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of Redmile Group, LLC, its manager
    Date:04/24/2026
     
    RedCo II Master Fund, L.P.
     
    Signature:/s/ Jeremy C. Green
    Name/Title:Managing Member of RedCo II (GP), LLC, General Partner of RedCo II Master Fund, L.P.
    Date:04/24/2026
    Get the next $NRIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRIX

    DatePrice TargetRatingAnalyst
    6/29/2026$28.00Outperform
    Oppenheimer
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    11/24/2025$30.00Buy
    Truist
    10/21/2025$24.00Outperform
    Mizuho
    3/17/2025$16.00Market Perform
    Leerink Partners
    12/10/2024$35.00Buy
    BTIG Research
    12/6/2024$35.00Outperform
    BMO Capital Markets
    10/24/2024$35.00Buy
    UBS
    More analyst ratings

    $NRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Nurix Therapeutics with a new price target

    Oppenheimer resumed coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $28.00

    6/29/26 8:39:55 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Nurix Therapeutics from Equal-Weight to Overweight and set a new price target of $36.00

    1/8/26 8:12:12 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Nurix Therapeutics with a new price target

    Truist resumed coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $30.00

    11/24/25 9:17:24 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Ring Christine exercised 11,008 shares at a strike of $5.47 and sold $259,366 worth of shares (11,008 units at $23.56) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    7/2/26 6:02:59 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Hansen Gwenn sold $107,880 worth of shares (5,394 units at $20.00) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 115,005 units (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    6/25/26 6:49:10 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Ring Christine exercised 28,935 shares at a strike of $8.05 and sold $580,506 worth of shares (28,935 units at $20.06) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

    6/25/26 6:38:05 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Nurix Therapeutics Inc.

    10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)

    7/9/26 4:12:07 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    7/9/26 4:09:51 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)

    6/11/26 7:06:57 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration includes comprehensive clinical development plan in malignant hematology and enables expansion of bexobrutideg into chronic spontaneous urticaria (CSU) and multiple sclerosis (MS) Presented clinical data update at the European Hematology Association (EHA) supporting bexobrutideg's potential as a best-in-class BTK degrader across multiple lines of therapy in CLL Well capitalized with cash, cash equivalents and marketable securities of $443.5 million as of May 31, 2026, and pro-forma cash

    7/9/26 4:01:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

    Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas

    7/6/26 11:19:00 AM ET
    $CTMX
    $GTBP
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

    High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June

    6/11/26 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Leadership Updates

    Live Leadership Updates

    View All

    Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

    Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignanciesCollaboration adds to Roche's oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton's Tyrosine Kinase (BTK) protein, potentially overcoming existing resistance mechanisms found with current standard-of-care BTK inhibitors Basel, 08 June 2026 - Roche ((SIX: RO, ROP, OTCQX:RHHBY) announced today that it has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX). Under the terms of

    6/8/26 1:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

    SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previously served as Chief Development Officer and Chief Oncology Officer of Pfizer Oncology and as Chief Medical Officer and interim Chief Executive Officer of Seagen Inc., has had a distinguished career in hematology and oncology and over two decades of leadership experience in drug development and commercialization. "Roger

    11/10/25 7:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi

    4/8/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Financials

    Live finance-specific insights

    View All

    Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

    Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development plan in malignant hematology builds on the ongoing pivotal program in chronic lymphocytic leukemia (CLL) and includes therapeutic combination regimens across B cell malignancies Clinical development plan also includes expansion into neurology and immunology with plans for Phase 2 trials in multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) Nurix to receive an upfront cash payment of $700 million and is eligible to receive development, regulatory and sales milesto

    6/8/26 1:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

    600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bexobrutideg as potential best-in-class BTK degrader profile Nurix will host an investor webcast today, Wednesday, October 22nd, at 8:00 a.m. EDT SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced t

    10/22/25 6:00:00 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

    Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforces Nurix's scientific leadership and platform strength in targeted protein degradation Nurix remains on track to initiate pivotal trials of bexobrutideg in 2025 Data are being presented at the 30th European Hematology Association Congress (EHA2025) Company will host a webcast conference call today, June 12, 2025, at 8:00 a.m. ET (2:00 p.m. CEST) SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clin

    6/12/25 6:59:59 AM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 9:00:57 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:21:48 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

    SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

    11/14/24 4:08:39 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care